Back

TRT Side Effects: Trial Data and Monitoring

Updated November 22, 2026

By GetOPT Review Team · November 22, 2026 ·Part of our Trt Guide

TRT side effects depend on your baseline health, your medication formulation, and how closely a physician tracks your blood markers. When you begin testosterone replacement therapy for diagnosed deficiency, physician oversight is part of the guideline's approach. Evidence from the TRAVERSE trial shows that transdermal testosterone gel did not increase primary cardiovascular events compared with placebo in men with cardiovascular risk, though therapy can elevate hematocrit and increase red blood cell concentration.3 The guideline includes lab monitoring of hematocrit in the first year.

The First-Year Monitoring Framework for Testosterone Therapy

The Endocrine Society guideline describes a standardized monitoring plan for the first year of treatment. According to the Endocrine Society clinical practice guideline, testosterone therapy is recommended for men with symptomatic deficiency after a discussion of potential benefits, risks, and monitoring requirements.1 Involving you directly in these clinical decisions ensures your treatment aligns with your medical history and personal goals.

The Endocrine Society advises that your clinician should evaluate your symptoms, monitor for adverse effects, and confirm medication compliance throughout treatment.1 Your doctor also measures your serum testosterone concentration and hematocrit concentration, while assessing your prostate cancer risk during your first year on therapy.1 The guideline suggests titrating your dose to maintain your testosterone levels in the mid-normal range during treatment.1

Regular blood testing through a comprehensive testosterone blood test provides the objective data your prescriber needs to evaluate your response. Review your lab schedule with your doctor at your initial consultation so you know when blood draws occur during your first year.

Are your TRT side effects being monitored?

Your Opt Health membership includes a lab panel, a physician's review, and follow-up testing.

Erythrocytosis and Blood Thickness Across Formulations

Erythrocytosis represents an increase in red blood cell mass that occurs more frequently with specific testosterone delivery methods. A clinical review by Ohlander and colleagues confirms that the risk of developing erythrocytosis compared with controls is well established in men receiving testosterone therapy.3 Short-acting injectable formulations carry the highest associated incidence of erythrocytosis compared with other delivery options.3

Elevated blood thickness from increased red blood cell concentration increases the potential risk for vascular complications, though current clinical evidence supporting a direct relation between testosterone therapy and vascular complications remains limited.3 The biological mechanism behind this process and its exact role in thromboembolic events remain unclear, even though some published data suggest an increased risk of cardiovascular events resulting from testosterone-induced erythrocytosis.3

Formulation matters, since short-acting injectables carry the highest incidence. For management detail, see how to lower hematocrit on TRT. Discuss formulation choices with your doctor before starting therapy, particularly if you have a personal history of elevated red blood cell counts.

Cardiovascular Safety Findings in the TRAVERSE Trial

The TRAVERSE trial demonstrated that testosterone gel did not increase major adverse cardiac events compared with placebo in men with cardiovascular risk factors.2 The study was a multicenter, randomized, double-blind, placebo-controlled trial evaluating 5,246 men between 45 to 80 years of age.2 Every participant had hypogonadism symptoms, two fasting testosterone levels under 300 ng per deciliter, and either preexisting cardiovascular disease or a high risk of developing it.2 Participants were randomized to receive daily transdermal 1.62% testosterone gel, adjusted to keep testosterone between 350 and 750 ng per deciliter, or a matching placebo gel.2

Over a mean treatment duration of 21.7 months and a mean follow-up of 33.0 months, a primary cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 182 patients (7.0%) in the testosterone group compared with 190 patients (7.3%) in the placebo group.2 This yielded a hazard ratio of 0.96 (95% CI 0.78 to 1.17; P<0.001 for noninferiority), establishing that testosterone replacement therapy was noninferior to placebo for major cardiovascular events in this population.2

The investigators observed a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group compared with placebo.2 Alongside the neutral primary result, these findings are worth weighing with your physician. Balancing these trial results against the documented TRT benefits helps you decide whether therapy fits your goals. Review your cardiovascular history and baseline kidney markers with your doctor before deciding is TRT worth it for your situation.

Clinical Contraindications and Reproductive Considerations

Certain preexisting medical conditions require you to delay or avoid testosterone therapy to prevent serious health complications. The Endocrine Society guideline recommends against starting testosterone therapy if you have breast or prostate cancer, a palpable prostate nodule or induration, or an elevated hematocrit.1 Therapy should also be avoided if you have untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, thrombophilia, or if you had a myocardial infarction or stroke within the past 6 months.1

For prostate health, the guideline advises against initiation if your prostate-specific antigen (PSA) level is above 4 ng/mL.1 It also recommends against starting therapy if your PSA is above 3 ng/mL and you have an increased risk of prostate cancer (such as African American men or men with a first-degree relative diagnosed with prostate cancer) without further urological evaluation.1

The guideline also recommends against starting testosterone therapy if you are planning fertility in the near term.1 Understanding does TRT affect fertility allows you to discuss alternative fertility-preserving protocols with your prescriber before beginning care. While discussions surrounding therapy often mention skin acne, breast tenderness, or testicular shrinkage, the clinical sources reviewed here do not quantify their exact rates. Discuss your prostate and fertility plans with your physician before starting.

The Opt Take on TRT Side Effects

Monitoring and managing TRT side effects involves continuous physician oversight, comprehensive diagnostic data, and personalized protocol adjustments. At Opt Health, we begin with a blood panel of 55+ biomarkers.

The pattern we see most often is a single out-of-range value with no trend behind it. A dedicated Opt Health physician evaluates your blood work against your physical symptoms and medical history. We re-test every three to four months.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Clinical guidelines emphasize that serum testosterone, hematocrit, and prostate cancer risk are monitored during testosterone therapy.1 Short-acting injectable testosterone carries the highest documented incidence of erythrocytosis compared with other formulations.3 While men often inquire about acne, breast tenderness, or sleep apnea, the clinical sources reviewed here do not quantify incidence rates for those specific conditions. Your physician can discuss your individual risk profile for these symptoms during your consultation.

Evidence from the TRAVERSE trial demonstrated that testosterone replacement therapy was noninferior to placebo for major adverse cardiac events in men with preexisting cardiovascular disease or elevated cardiovascular risk.2 In that trial, 7.0% of men using transdermal testosterone gel experienced a cardiovascular death, nonfatal heart attack, or nonfatal stroke, compared with 7.3% of men receiving placebo.2 The trial did observe a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, which is worth discussing with your physician.2

Testosterone therapy increases your risk of developing erythrocytosis, a condition where your body produces an elevated concentration of red blood cells.3 Clinical research confirms this risk is well established compared with controls, with short-acting injectable formulations showing the highest incidence.3 The guideline's first-year monitoring plan includes measuring hematocrit.1,3

The Endocrine Society recommends against starting testosterone therapy if you plan to have children in the near term, have breast or prostate cancer, or have elevated hematocrit.1 You should also avoid therapy if you have a palpable prostate nodule, PSA above 4 ng/mL (or above 3 ng/mL in men at increased risk of prostate cancer, without further urological evaluation), untreated severe sleep apnea, severe urinary symptoms, uncontrolled heart failure, thrombophilia, or had a heart attack or stroke within the past 6 months.1

Your doctor should monitor you using a standardized protocol during your first year of therapy that evaluates your symptoms, adverse reactions, and medication compliance.1 This clinical plan includes measuring your serum testosterone and hematocrit concentrations, along with assessing your prostate cancer risk.1 Clinical guidelines suggest adjusting your dose to keep your testosterone levels in the mid-normal range during treatment.1

Side effects of testosterone therapy are caught by repeat labs, which makes monitoring the practical backbone of safe care. An Opt Health membership gives you a 1:1 consultation with an Opt Health physician to review your results and set a plan. We run the panel, a physician reads it, and we re-test every three to four months so your care adjusts as your markers change.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/.
  2. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/.
  3. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6(1):77-85. https://pubmed.ncbi.nlm.nih.gov/28526632/.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.

Start Today

Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.